The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in patients with bipolar disorder ages 18-65. The main questions it aims to answer are:
* Can the investigators compare the distribution of obesity characteristics (hungry brain, hungry gut, emotional hunger) between bipolar patients and non-bipolar participants (comparing from IRB #24-002375)?
* Can the investigators evaluate the feasibility of anti-obesity medication (AOM) in patients with bipolar disorder?
Participation will last for about 20 weeks and includes 8 in-person study visits, up to 11 phone call visits, and 13 virtual group therapy sessions. The first visit lasts about 2 hours and includes going over the informed consent form, a diagnostic interview to confirm diagnosis, gathering vital signs, mood questionnaires, an ECG, a blood draw, and urine drug and pregnancy tests (if applicable). The second visit lasts about 6-7 hours and involves multiple procedures and completing questionnaires to determine which study drug would allow participants to lose weight most effectively. At the third visit, participants will be assigned to take one of three FDA approved medications for weight loss: Semaglutide (Wegovy®), Naltrexone/Bupropion (Contrave®), or Phentermine/Topiramate (Qsymia®). It is possible that participants could be assigned to a group that receives no study medication. All participants will be enrolled in a 12-week virtual group therapy program targeted for weight loss. On this third visit the investigators will also gather vital signs, and participants will give a sample of blood. After the third visit, participants will come in for study visits every 4 weeks for 20 weeks (5 visits) to assess medication adherence, vitals, and answer questions about mood and eating (participants will also give a sample of blood at the 8-week and 20-week visits). For participants assigned to a study medication, the study team will call every week for the first 2 months (excluding in-person visit weeks) to assess mood and safety. After the first 2 months, the study team will call the participant every two weeks in between in-person visits. Participants will be compensated for time spent in this study. Participants assigned to a study medication will also be given the option to participate in the open-label phase of the study, which involves 3 follow-up visits (weeks 24, 36, and 48) over 7 months after the 20-week trial. During this phase, participants can continue to take the medication through their clinical care provider.

开始日期2026-01-19

申办/合作机构

Mayo Clinic

[+1]

NCT06620562

/ Recruiting临床4期IIT

Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet - A Randomized Controlled Trial

The goal of this clinical trial is to assess the impact of combination therapy with Naltrexone-Bupropion (NB) in the post-operative period of sleeve gastrectomy (SG). on a) weight loss, b) resolution of comorbidities and c) eating behaviors.
Researchers will compare SG-NB group with SG-placebo group to see if they experience significantly higher excess weight loss (EWL) at 12 and 24 months and if there is a significantly higher percentage of patients with an EWL above 50% in the SG-NB group versus in the SG-placebo group.
Participants will be randomized 1:1 to SG in combination with NB versus SG with placebo. Patients will be started one month after surgery on a progressive dose of Naltrexone/Bupropion extended-release or placebo. Duration of therapy will be 24 months.Both groups will benefit from behavioral and nutritional support.

开始日期2025-06-04

申办/合作机构

Université Laval

[+1]

NCT06845345

/ Enrolling by invitation临床4期IIT

Effect of Mediterranean Diet Combined With Intermittent Fasting on Liver Fibrosis Compared to Naltrexone/Bupropion in People With Cardiometabolic Risk Factors

In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and even death of the liver. Losing weight can help reduce this. Losing weight can be done with medication such as naltrexone/bupropion, which is often prescribed to people with cardiometabolic diseases, but losing weight can also be done with diet. In this study, the investigators want to combine a Mediterranean diet (with lots of vegetables, fruits, whole grain products, nuts and olive oil) with intermittent fasting. In addition participants are not allowed to eat after the evening meal. The investigators will compare this with a group of participants receiving naltrexone/bupropion, to see if a diet with intermittent fasting might be better for reducing liver steatosis and fibrosis in people with cardiometabolic diseases.

开始日期2025-04-14

申办/合作机构-

100 项与盐酸纳曲酮/盐酸安非他酮相关的临床结果

登录后查看更多信息

100 项与盐酸纳曲酮/盐酸安非他酮相关的转化医学

登录后查看更多信息

100 项与盐酸纳曲酮/盐酸安非他酮相关的专利（医药）

登录后查看更多信息

项与盐酸纳曲酮/盐酸安非他酮相关的文献（医药）

2026-08-01·Clinical Obesity

Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended‐Release Tablet ( NB ‐ ER ) for Weight Maintenance in Adult Patients After a 6‐Month Intensive Behaviour Modification Program Combined With Meal Replacements

Article

作者: Denescu, Liviu ; Chetty, V. Tony ; Balodis, Iris M. ; Foster, Gary ; Zevin, Boris ; Damjanovic, Suzana ; Elsharif, Adell

ABSTRACT:

The prevalence of obesity is increasing worldwide, with approximately nine million people affected in Canada. Obesity is associated with high rates of morbidity and mortality as well as significant healthcare costs and economic burden. The primary therapeutic options for weight maintenance and treatment of weight regain include behaviour modification, lifestyle intervention and pharmacotherapy. This randomised, double‐blind, placebo‐controlled, crossover trial aimed to determine the effect of a fixed‐dose, extended‐release combination of naltrexone and bupropion (NB‐ER) (commonly known as Contrave) on weight maintenance and further weight loss following the intensive portion of a behaviour modification program. The results from this study demonstrate that after an intensive lifestyle intervention program, treatment with NB‐ER for six months prevented weight regain compared to placebo. Additionally, a greater proportion of subjects experienced weight maintenance and less absolute weight regain on NB‐ER compared to placebo, supporting the use of NB‐ER as an effective option for weight maintenance in patients with significant prior weight loss.

2026-03-01·Obesity pillars

Outcomes of obesity medications in those with low response to a low-energy diet meal replacement programme: An observational study

Article

作者: Shand, James ; Murphy, Rinki ; Jiang, Yannan

Background:

It is not known how individuals respond to liraglutide or naltrexone/bupropion following low-response to a structured meal replacement low energy diet (MR-LED) programme.

Methods:

This was a retrospective observational study conducted at a specialist weight management service using MR-LED with intensive behavioural therapy (IBT). Adults were considered for obesity medication if they did not lose at least 5 % body weight in the first 4 weeks of the intensive MR phase, 10 % after the total 12 week MR phase or regained >4 kg either during the stepped food reintroduction or weight maintenance phases. Eligible individuals were offered liraglutide 3.0 mg (LIRA) or naltrexone/bupropion (NB32) for 13 weeks (including dose titration). The primary outcome was the proportion of individuals achieving ≥5 % weight reduction after 13 weeks of treatment. Completers were defined as those who had a body weight measured between 10 and 16 weeks and did not discontinue the medication before this period.

Results:

Of 114 people offered obesity medications, 85 accepted (67 LIRA, 18 NB32). 46 individuals completed 13 weeks' treatment and 11 (24 %) achieved ≥5 % weight reduction. Among completers (54 %), the mean weight change was -4.4 kg (-2.4 %), and was -2.7 kg (-1.5 %) for the total treated cohort using last weight carried forward on missing data. Those achieving ≥5 % weight reduction were more likely to be male and had lower prevalence of diabetes, binge eating, anxiety or depressive symptoms at baseline.

Conclusion:

People who do not respond to a MR-LED with IBT have lower than anticipated weight reduction on subsequent treatment with first-generation obesity medications.

2024-05-01·International journal of obesity (2005)

Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective

Article

作者: Lau, David C W ; Chan, Katalina ; Lamotte, Mark ; Luckevich, Maria ; Larsen, Sara ; Olivieri, Anamaria-Vera ; Muratov, Sergey

Abstract:

Objectives:

This study aimed to assess the cost-effectiveness of weight-management pharmacotherapies approved by Canada Health, i.e., orlistat, naltrexone 32 mg/bupropion 360 mg (NB-32), liraglutide 3.0 mg and semaglutide 2.4 mg as compared to the current standard of care (SoC).

Methods:

Analyses were conducted using a cohort with a mean starting age 50 years, body mass index (BMI) 37.5 kg/m2, and 27.6% having type 2 diabetes. Using treatment-specific changes in surrogate endpoints from the STEP trials (BMI, glycemic, blood pressure, lipids), besides a network meta-analysis, the occurrence of weight-related complications, costs, and quality-adjusted life-years (QALYs) were projected over lifetime.

Results:

From a societal perspective, at a willingness-to-pay (WTP) threshold of CAD 50 000 per QALY, semaglutide 2.4 mg was the most cost-effective treatment, at an incremental cost-utility ratio (ICUR) of CAD 31 243 and CAD 29 014 per QALY gained versus the next best alternative, i.e., orlistat, and SoC, respectively. Semaglutide 2.4 mg extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg and remained cost-effective both under a public and private payer perspective. Results were robust to sensitivity analyses varying post-treatment catch-up rates, longer treatment durations and using real-world cohort characteristics. Semaglutide 2.4 mg was the preferred intervention, with a likelihood of 70% at a WTP threshold of CAD 50 000 per QALY gained. However, when the modeled benefits of weight-loss on cancer, mortality, cardiovascular disease (CVD) or osteoarthritis surgeries were removed simultaneously, orlistat emerged as the best value for money compared with SoC, with an ICUR of CAD 35 723 per QALY gained.

Conclusion:

Semaglutide 2.4 mg was the most cost-effective treatment alternative compared with D&E or orlistat alone, and extendedly dominated other pharmacotherapies such as NB-32 or liraglutide 3.0 mg. Results were sensitive to the inclusion of the combined benefits of mortality, cancer, CVD, and knee osteoarthritis.

项与盐酸纳曲酮/盐酸安非他酮相关的新闻（医药）

2026-09-29

·BioSpace

Azurity Pharmaceuticals Showcases Growth and Commercial Momentum ahead of CPHI Milan 2026

Recent approvals and international expansion underscore the company's evolution as a global specialty pharmaceutical company focused on reimagining medicine for real-world patient needs Woburn, MA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, a privately held specialty pharmaceutical company, today highlighted continued momentum across its global business including a commercial presence in more than 50 countries and a diversified portfolio of medicines across 11 therapeutic areas. Building on a series of recent regulatory approvals, strategic partnerships, and portfolio investments, Azurity continues to accelerate access to medicines designed for the realities of everyday life. The update comes as pharmaceutical leaders prepare to gather for CPHI Milan, taking place October 6-8, 2026, where Azurity executives will share perspectives on the future of pharmaceutical innovation, commercialization, and supply chain collaboration. “Azurity was built on the belief that medicine should work in the realities of everyday life,” said Ronald Scarboro, Chief Executive Officer, Azurity Pharmaceuticals . “What began as a mission to address unmet patient needs has grown into a global enterprise built to reimagine medicine for the real world. Our momentum reflects the power of an operating model designed to recognize opportunities others may have overlooked and turned them into meaningful solutions for patients around the world.” Recent regulatory milestones, portfolio investments, and commercialization activities have expanded Azurity's capabilities across development, commercialization, and international market access. New additions to the portfolio, including Contrave® and Mysimba®, reflect the company's disciplined approach to identifying high-potential assets and creating new opportunities to deliver value for patients, providers, and healthcare systems. The 2025 acquisition of Covis Pharma marked another important milestone, expanding Azurity's presence to more than 50 markets worldwide and enhancing its ability to bring differentiated medicines to patients around the world. Azurity’s operating model brings together business development, formulation development, regulatory expertise, commercial execution, and lifecycle management. This integrated approach enables the company to identify opportunities, develop differentiated products, and support their availability across a range of conditions, dosage forms, care settings and markets. “Combining local market insight with global scale is increasingly important as healthcare systems evolve,” said Ronald van der Rol, Chief Commercial Officer, Europe and International, Azurity Pharmaceuticals . “Across Europe and other international markets, we see opportunities to bring proven therapies to more patients, build meaningful local partnerships, and create sustainable value. Our model gives us scale, expertise, and flexibility to pursue those opportunities while responding to distinct needs of individual markets.” Azurity executives will take the stage at CPHI Milan to address key challenges in medicine design and global supply, with three speaking engagements on the official program : Ronald Scarboro, Chief Executive Officer , will deliver a presentation on how patient needs and real-world use can inform medicine design on October 6, from 11:00–11:30 a.m., at Packaging & Device Innovation, Hall 11, 11A49. Gyan Singh, Senior Vice President of Operations, will join a panel discussion, bringing an operations perspective on supply chain integrity, strategic partnerships, and the reliable delivery of medicines to patients on October 7, from 4:15–5:00 p.m., at Supply & Formulation Excellence, Hall 2, Room 2A132. Hardik Shah, Vice President of CMC Product Development, will join a roundtable titled “Accelerating Early Clinical Development” at NH Hotel Milano Fiera on Oct ober 7 , from 6:00-7:00 p.m. All times are local to Milan. Visit Azurity at Integrated Pharma, Hall 7, Stand 7B129, to learn more about the company’s portfolio, international operations, and approach to pharmaceutical development and commercialization. To connect during CPHI Milan, schedule a meeting with the Azurity team . About Azurity Pharmaceuticals Azurity Pharmaceuticals is a privately held global pharmaceutical company dedicated to redefining medicine for the real world. Azurity’s first-in-class enterprise model challenges the status quo by rethinking how therapies are designed, delivered, and accessed. With more than 70 medicines across 11 therapeutic areas, Azurity’s mission is fueled by a growing portfolio that reaches millions of people in more than 50 countries. Learn more at  and LinkedIn . Media Contact: media@azurity.com ©2026 Azurity Pharmaceuticals, Inc. All rights Reserved. This press release may contain forward-looking statements subject to risks and uncertainties. CONTACT: Media Relations Azurity Pharmaceuticals media@azurity.com

并购

2026-08-21

·百度百家

BMJ重磅研究：19种减肥药大比拼，华西团队分析了近10万人的数据告诉你哪种最有效

司美格鲁肽火遍全网之后，每个人都在问：到底哪种减肥药最好？华西团队分析了262项研究、近10万人的数据，给出了迄今最全的答案。 2026年7月8日，四川大学华西医院李舍予教授团队在《英国医学杂志》（BMJ，影响因子55.1）发表了一项系统评价与网状Meta分析。研究纳入262项随机对照试验、共计99,791名成人超重或肥胖受试者，随访时间从12周到172周不等，评估了19种已上市或正在审批中的体重管理药物，覆盖了24项患者重要结局。这不是某一家药厂的临床试验，而是把全球已有的高质量证据全部整合在一起，用统计学方法让不同药物在同一个证据网络里直接PK。结论的可靠性和全面性，远超任何单一研究。一、什么是网状Meta分析？为什么它能回答哪种药最好传统的临床试验大多是这样设计的：新药A vs 安慰剂，或者新药B vs 生活方式干预。这种设计能告诉我们A有没有效果、B有没有效果，但回答不了一个更实际的问题：A和B哪个更好？因为很少有人会花钱做A和B的头对头比较——尤其是当两种药来自不同公司时。网状Meta分析的妙处在于：它不需要药物之间真的做过头对头试验。只要A和C比过、B也和C比过，就可以通过C这个共同对照，间接推算出A和B的相对效果。把19种药物全部放进同一个证据网络里，就能两两比较，排出一个相对优劣的序列。李舍予教授把这项研究的特点概括为药物全、结局全。药物全，是指覆盖了目前市面上和研发管线里的19种体重管理药物，不限于最火的GLP-1类。结局全，是指不只关注体重下降了多少斤，还纳入了腰围、脂肪量、瘦体重、生活质量、心肾结局，以及胃肠道不良反应、胆囊相关疾病、疲劳和因不良反应停药等患者关心的指标。二、这种全景式的比较，才能真正帮助医生和患者做出个体化选择。核心发现一：GLP-1类药物整体领先，但内部差异很大研究结果不出意料：GLP-1受体激动剂（GLP-1RA）整体表现最好，在减重幅度上明显优于其他类药物。但出人意料的是，同为GLP-1RA，不同药物之间的效果差距也不小。研究按照减重效果对不同药物进行了排序。排在第一梯队的，是以替尔泊肽（Tirzepatide）为代表的GLP-1/GIP双靶点激动剂。替尔泊肽在多项结局中表现突出，减重幅度在现有药物中居于前列，同时心血管风险指标也有改善。排在第二梯队的，包括司美格鲁肽（Semaglutide）等强效GLP-1RA。司美格鲁肽的减重效果已经经过STEP系列研究反复验证，2.4毫克剂量下44周可减重12%到15%，这次网状Meta分析进一步确认了它在GLP-1类中的领先地位。排在后面梯队的，包括一些早期的GLP-1RA如利拉鲁肽（Liraglutide），以及非GLP-1类药物如奥利司他（Orlistat）、芬特明-托吡酯复方（Phentermine-Topiramate）、纳曲酮-安非他酮复方（Naltrexone-Bupropion）等。这些药物要么减重幅度较小，要么不良反应发生率较高，要么长期安全性数据不足。这里需要强调一个关键认知：减重幅度大不等于就是最好的选择。核心发现二：减重药不是越强越好，个体化选择才是关键这是这项研究最有价值的启示。很多患者的思维是：我要选减重效果最强的药。但临床医生的思维是：在疗效、安全性、耐受性、成本、患者偏好之间找平衡。举个例子：替尔泊肽减重效果最好，但它的胃肠道不良反应发生率也更高。研究数据显示，部分患者因恶心、呕吐、腹泻等不良反应而停药。如果你本身胃肠道敏感，或者工作需要频繁出差、不能随时找到厕所，那么替尔泊肽可能不是你的最优选择。再比如，芬特明-托吡酯复方的减重效果也不错，但它有中枢神经系统副作用（如注意力不集中、感觉异常），且有致畸风险，育龄期女性使用需要严格避孕。如果你是一位有生育计划的年轻女性，这个药就不适合。奥利司他是非处方药，方便获取，但它的主要不良反应是脂肪泻——吃得太油就会拉肚子，而且长期可能影响脂溶性维生素吸收。如果你平时饮食控制不好、爱吃油腻，这个药可能让你很尴尬。司美格鲁肽的效果和安全性平衡较好，但它是皮下注射，每周一针。对打针有心理恐惧的人，依从性会受影响。而且它价格不低，部分地区尚未纳入医保，经济负担也是现实考量。所以，减重药物的选择不是越强越好，而是越适合越好。这个适合，需要医生根据你的年龄、性别、合并症、药物耐受史、经济状况、生活方式和个人偏好综合判断。网状Meta分析的价值，就是为这种个体化决策提供全面的证据地图，而不是替所有人开同一个药方。核心发现三：心血管获益有差异，不只是减重那么简单肥胖患者用减肥药，目标不只是瘦，更是降低心血管风险。这项研究特别关注了不同药物对心肾结局的影响。结果显示，部分GLP-1RA在减重的同时，还能显著降低心肌梗死、卒中和心力衰竭的风险。这种心血管保护作用，在SELECT研究（司美格鲁肽）和SURPASS系列研究（替尔泊肽）中都有独立验证。机制上，GLP-1RA除了通过减重改善代谢，还可能直接作用于血管内皮、抑制炎症反应、改善心肌能量代谢。但并非所有减重药物都有心血管获益。有些药物虽然能减重，但对心血管结局的影响中性甚至不利。还有些药物的心血管安全性数据尚不充分，无法得出结论。对于有心血管病史或高危因素的肥胖患者（如高血压、糖尿病、血脂异常），选择具有心血管保护证据的药物，是双重获益。而对于年轻、低风险的患者，心血管获益可能不是首要考量，减重幅度和耐受性更重要。研究还关注了肾脏结局。肥胖是慢性肾病的独立危险因素，部分GLP-1RA在减重的同时还能降低尿蛋白、延缓肾功能下降。这对合并糖尿病肾病的患者尤其重要。核心发现四：不良反应谱不同，停药率差距明显这项研究的另一个亮点，是系统比较了不同药物的不良反应谱和停药率。胃肠道反应是GLP-1RA最常见的不良反应，包括恶心、呕吐、腹泻、便秘。但不同药物、不同剂量之间差异很大。一般来说，起始剂量较低、逐步滴定到目标剂量，可以显著减轻胃肠道不适。研究还发现，随着用药时间延长，胃肠道反应会逐渐减轻，大多数患者能耐受。胆囊相关疾病在快速减重患者中风险增加，部分药物的数据提示需关注。疲劳和乏力在非GLP-1类药物中更常见。停药率是反映患者耐受性和药物可接受性的综合指标。研究数据显示，因不良反应停药的比率在不同药物间差异显著。有些药物减重效果很好，但停药率也高，说明实际使用中很多患者坚持不下来。这对长期体重管理是个重要问题——毕竟，减重要坚持，不反弹才有意义。研究采用GRADE证据分级标准评估了各项结局的证据确定性。这意味着，每一项结论都有明确的证据强度标注，帮助医生和患者判断：这个结论是强推荐还是弱推荐，是高质量证据还是低质量证据。三、哪些人建议药物干预？BMI不是唯一标准看了这么多药物比较，你可能想问：我到底需不需要用药？根据国内外指南，减重药物治疗的主要适应症是：BMI大于等于30，或BMI大于等于27且伴有至少一种体重相关合并症（如高血压、2型糖尿病、血脂异常、睡眠呼吸暂停等）。但BMI不是唯一标准。腰围、体脂率、内脏脂肪面积，以及是否存在代谢综合征，都是医生评估的重要指标。同样是BMI 28，一个人腰围正常、代谢指标正常，另一个人腰围超标、甘油三酯高、血糖临界，两人的干预策略完全不同。此外，生活方式干预是所有减重治疗的基石。无论是否用药，饮食控制、增加运动、行为干预都是必须的。药物只是辅助，不能替代健康的生活方式。研究显示，药物+生活方式干预的效果优于单独用药，也优于单独生活方式干预。对于BMI小于27的人群，目前不建议使用减重药物。通过调整饮食和运动，大多数人能实现5%到10%的体重下降，足以带来显著的代谢改善。四、写在最后：不要自行购买海外版减肥针这项研究发表后，社交媒体上可能会出现各种代购海外版司美格鲁肽、替尔泊肽的广告。作为一个医生，我必须说一句：不要买。第一，来源不明。海外代购的药物可能是假药、过期药，或者运输过程中保存条件不达标导致失效。GLP-1RA是生物制剂，对储存温度要求严格，非正规渠道无法保证冷链。第二，没有医生指导。减重药物有明确的适应症和禁忌症，需要评估心血管风险、肝肾功能、药物相互作用。自行用药可能用错剂量、忽略禁忌症、错过不良反应的早期信号。第三，没有随访管理。用药期间需要定期监测体重、血糖、血压、肝肾功能，评估疗效和安全性。没有医生的随访，你无法判断药物是否有效、是否需要调整剂量、是否应该停药。第四，停药后反弹。减重药物一旦停药，如果没有建立良好的生活习惯，体重会反弹。医生能帮助你制定长期管理方案，而不是单纯依赖药物。减重药物的选择是一个医学决策，不是购物决策。无论你最终用哪种药，都应该在内分泌科或减重专科医生的指导下，经过全面评估后再开始。数据来源：四川大学华西医院李舍予教授团队，《英国医学杂志（BMJ）》2026年7月8日发表；2026肥胖大会（COC2026）李舍予教授专访报道。

临床结果

2026-07-27

·中国生物器材网

减肥药物的作用机制和发展历程及新靶点和新突破

Section.01 肥胖症：你不知道的那些事儿肥胖症——源于中枢神经系统对体重的控制功能受损[1]。是的，你没有听错。大约三十年前，人类首次发现与单基因肥胖相关的基因，即编码瘦素的 LEP 基因和编码瘦素受体的 LEPR 基因。瘦素，是由白色脂肪组织 (尤其是脂肪细胞)产生的激素，其分泌在空腹状态下减少，在摄入营养后增加。它主要通过激活厌食性神经通路来调节能量平衡，尤其能够刺激下丘脑的多个核团，从而促进饱腹感和减轻体重。其中，瘦素-黑皮质素通路 (Leptin-melanocortin pathway) 是下丘脑弓状核 (Arcuate nucleus) 和旁正中核 (Paramedian nucleus) 调节饱腹信号和能量消耗的主要参与者 (图 1) 。图 1. 下丘脑核团中瘦素-黑皮质素通路示意图[1]。尖头箭头表示刺激，圆头箭头表示抑制。一方面，进食后，肠道的 L 细胞会分泌大量 GLP-1，GLP1-R 的激活会促进两种神经元群中瘦素受体 (LEPR) 的激活。SH2B1 可增强 LEPR 对食欲神经元中 AgRP (M4CR 拮抗剂) 的抑制作用。抑制 AgRP 与饱腹信号 α-MSH 竞争结合 MC4R。否则，AgRP 结合 MC4R 会阻断其下游信号，从而促进食欲、抑制能量消耗并导致体重增加。另一方面，脂肪细胞中的瘦素基因 (LEP) 合成瘦素，瘦素激活其受体 (LEPR)。SH2B1 和 SRC 在瘦素与其受体结合后被激活，增强瘦素在厌食神经元中对 PCSK1 酶活性的诱导，将 POMC 转化为 α-MSH (MC4R 激动剂)。α-MSH 是 MC4R 的天然配体，可激活 MC4R。MRAP2 作为 MC4R 的辅助伴侣蛋白，负责将该受体靶向定位到初级纤毛，这是下丘脑神经元执行能量稳态调节的关键位置。同时，BBSome 八聚体复合物介导跨膜蛋白 (包括 ADCY3) 在初级纤毛中的定位富集，是 MC4R 进行正常信号转导的结构基础。当 α-MSH 激活 MC4R 后，会诱发下游 G 蛋白级联反应，将 ATP 催化转化为 cAMP，进而调节相关基因转录以抑制食欲，诱导“吃饱了”信号并增加能量消耗。瘦素释放不足或瘦素信号传导受损会导致营养过剩、能量消耗减少，并最终导致肥胖和其他慢性疾病的发生。当然，长期暴露于瘦素过载状态也不行，会引发中枢性”瘦素抵抗”。类似“胰岛素抵抗”，即使体内脂肪充足且瘦素水平很高，大脑也无法接收到这个信号，导致持续的饥饿感、强烈的食欲和新陈代谢减慢，同样会导致肥胖和其他慢性疾病的发生[2]。当前！“减重药”的研究正如火如荼地开展，更是在“见效快、躺着也能瘦、价格大跳水”等营销宣传中引发了全球热潮…… Section.02 盘一盘：那些「抗肥胖药物」！历史上，许多抗肥胖药物在获批后便宣告失败，其中大多数与心血管不良反应有关，如Sibutramine；或增加自杀风险，如利莫那班 (Rimonabant) ；或导致药物依赖和滥用，如Methamphetamine；由于存在成瘾性或快速耐受性，如Phentermine等药物仅被推荐用于短期治疗 (表 1)[3]。表 1. 减肥药物的发展历程。一、肠促胰素类似物肠胰激素药物通过刺激胰岛素分泌、减缓胃排空和增加饱腹感来控制血糖和减轻体重。正在进行 II 期临床试验的药物中，近一半是肠促胰素类似物，其中胰高血糖素样肽-1 (GLP-1)是基于肠胰激素的肥胖治疗方案的核心靶点[4]。『GLP-1 受体激动剂』司美格鲁肽你一定听过！“火出圈”的 GLP-1 受体激动剂，主要功能有 2 个：降糖、减重。最初是作为抗糖尿病药物研发的，当人体内 GLP-1 水平较高时也会作用于中枢神经系统抑制食欲，增加饱腹感，从而带来显著的减重效果 (图 2)。司美格鲁肽减重注射液 (Wegovy) 于 2021 年 6 月 4 日获 FDA 批准。2024 年 6 月 25 日，国家药品监督管理局 (NMPA) 批准司美格鲁肽注射液 (诺和盈) 在国内上市，用于长期体重管理。此外，更多用于治疗肥胖症的 GLP-1 受体单激动剂包括：注射类有 Liraglutide (利拉鲁肽，LIRA) 与 Semaglutida (司美格鲁肽，SEMA) 。口服类有 Semaglutida (司美格鲁肽)、Orforglipron (奥福格列隆) 和 Danuglipron (达格列汀) 等。 Tips: 据 2026 年美国糖尿病协会会议 (ADA) 披露，阿斯利康的口服小分子 GLP-1 受体激动剂 AZD5004 (elecoglipron)，进入 III 期临床研究。更有辉瑞公布的超长效 GLP-1 受体激动剂 Berobenatide，主打把”每周一针”变成”每月一针”，成为全球第一款“月注射”减重药潜力股。『GIP/GLP-1』动物模型研究表明 GIP 受体激动剂具有厌食作用，且在临床前模型中同时激活 GLP-1 和 GIP 受体比单独激活每个受体能带来更大的体重减轻效果[5]。Tirzepatida (替尔泊肽，TZP) 就是一种单分子 GIP/GLP-1 双重受体激动剂，基于 GIP 结构，其肽链经过结构修饰，可与 GLP-1 和 GIP 受体相互作用。其对 GIP 受体结合亲和力与天然 GIP 相当，对 GLP-1 受体亲和力比天然 GLP-1 低 5 倍[5][6]。 GIP拮抗也是一种潜在的肥胖治疗策略，临床前研究表明，它能改善代谢状况并减少食物摄入量 (图 2)。AMG133 是一种单克隆抗体，旨在拮抗 GIP 受体，并与两种修饰的 GLP-1 肽连接，可激活 GLP-1 受体，一项针对超重和肥胖人群的 AMG133 的 52 周 II 期临床试验正在进行中 (NCT05669599)。『GLP-1/胰高血糖素』胰高血糖素(glucagon) 由胰腺 α 细胞分泌，其激动剂能减少食物摄入并增加能量消耗 (图 2)。胰高血糖素受体/胰高血糖素样肽-1受体 (GCGR/GLP-1R) 双重激动剂主要有 Survodutide (BI 456906)、Pemvidutide (ALT-801)、Efinopegdutide (JNJ-64565111) 等。处于早期临床试验阶段的 GLP-1 和胰高血糖素共激动剂作为肥胖症的治疗方法包括 AZD9550 和 LY3305677 (NCT05623839)[5]。『GLP-1/GIP/胰高血糖素』 Retatrutide (瑞他鲁肽) 是目前研究最多的 GLP-1-GIP-GCG 三激动剂。它源自 GIP 分子，对人 GIP 受体的亲和力较高，而对 GLP-1 和胰高血糖素受体的亲和力较低。其肽链经过修饰，能同时激活体内的 GIP、GLP-1 和 GCGR 受体，增强其三种成分的厌食作用，延缓胃排空，增加能量消耗和减少热量摄入[6]。另一种三重激动剂 (HM15211) 正在进行Ⅰ期临床试验，目前尚未公布数据。 Tips: 近期，礼来在 ADA 会议上公布了 Retatrutide 的两项关键 III 期研究，其中针对肥胖的 TRIUMPH-1 达到主要终点和全部关键次要终点，披露显示， 12mg 剂量组肥胖人群 80 周平均减重 28.3%，近半数患者减重超 30%，最高剂量组平均减重 70 磅，创下大型 III 期肥胖药物减重的最高纪录。『胰淀素』胰淀素 (Amylin) 作用于脑干中的胰淀素受体，减少食物摄入，并通过延缓胃排空和抑制胰高血糖素分泌来改善葡萄糖代谢 (图 2)[5]。 Pramlintide (普兰林肽) 是第一个获批用于糖尿病管理的合成胰淀素类似物，体重减轻率最高可达 7.9%。 Cagrilintide (卡格列肽) 是一种新型长效胰淀素类似物——在一项 II 期临床试验中，每周一次的 Cagrilintide 可使体重减轻 6% 至 10.8%，且呈剂量依赖性。『GLP-1/胰淀素』 Cagrilintide (卡格列肽)，诺和诺德推出的一种新型长效胰淀素类似物，也是 Semaglutide 与长效胰淀素类似物 Cagrilintide 的固定复方制剂。该组合可谓强强联合，通过双重机制协同作用，更有效地减少饥饿感、增加饱腹感。 Tips: 同样，ADA 会议披露的数据显示，在 REIMAGINE 2 研究中，CagriSema 在降糖与减重方面均优于司美格鲁肽。目前，针对肥胖人群安全性和有效性的 3 期临床试验 (NCT05567796、NCT05394519、NCT05813925) 正在评估中。此外，一种口服 GLP-1 和胰淀素共激动剂 (Amycretin) 也正在开展早期临床试验。『PYY』进食后，肠道 L 细胞会与 GLP-1 共同分泌 PYY (Peptide YY)。分泌后，PYY 会被二肽基肽酶 -4 (DPP-4) 迅速切割成活性形式 (PYY 3-36)，进而作用于神经肽 Y 受体 2 型 (Y2R)。Y2R 受体存在于大脑中，其激动作用可减少食物摄入并增加饱腹感 (图 2)。长效皮下注射的 PYY 受体激动剂正在进行早期临床试验，作为肥胖症的治疗药物，可单独使用或与 GLP-1 受体激动剂联合使用 (NCT02568306 和 NCT03574584)[5]。二、胃肠道脂肪酶抑制剂目前临床上主流且合法的胃肠道脂肪酶抑制剂是 Orlistat(奥利司他)，是全球第一个 FDA 获批的非处方减肥药。该药物是一种饱和衍生物，来源于链霉菌 (Streptomyces toxytricini) 中的内源性利普司他汀 (lipstatin)。它通过抑制胃肠道腔内的胃脂肪酶和胰脂肪酶，减少膳食脂肪的全身吸收。图 3. 奥利司他调节脂质的作用机制[7]。 Orlistat 通过可逆性抑制肠道内的胃脂肪酶和胰脂肪酶来治疗肥胖。这些脂肪酶在膳食脂肪的消化过程中起着至关重要的作用，它们将甘油三酯分解成可吸收的游离脂肪酸和单甘油酯。Orlistat 与这些脂肪酶活性位点的丝氨酸残基共价结合，使其失活。脂肪酶的失活阻止了甘油三酯的水解，从而阻碍了游离脂肪酸的吸收。三、中枢神经系统受体调节剂 FDA 获批的中枢性药物，例如 Phentermine-Topiramate和 Naltrexone-Bupropion (纳曲酮-安非他酮，Contrave®)，通过调节大脑中的食欲发挥作用[8]。此外，Setmelanotide (Imcivree) 作为 MC4R 单靶点激动剂于 2020 年底获批上市，是 FDA 批准的罕见肥胖症突破性药物。另一款 MC4R 靶向药物 Bremelanotide (布美诺肽)，当属老药新用！于 2019 年获批上市后被发现具有减重效果，2025 年 3 月的临床数据显示，Bremelanotide 与 Tirzepatide 联合给药协同导致体重减轻增加。表 2. 目前国内 (NMPA) 国外 (FDA) 获批的减肥药物[3]。 Section.03 最前沿：新靶点 & 新突破一、新靶点：SIK 抑制剂 2026 年 6 月 2 日，Nature Communications 杂志发表标题为 "Targeting hypothalamic SIK3 to promote weight loss and improve glycemic control in mice" 的研究[9]。研究发现，肥胖小鼠下丘脑中 SIK3 呈高表达。使用抑制剂 GLPG3970 特异性地抑制促食欲 NPY 神经元中的 SIK3 可减少食物摄入，增加能量消耗，并促进白色脂肪组织褐变，从而使小鼠对高脂饮食诱导的肥胖产生抵抗力，显著降低体重和脂肪含量。并且，当 GLPG3970 与司美格鲁肽联用时，减重效果协同。图 4. SIK3 抑制剂 GLPG3970 单用/联合司美格鲁肽促进体重减轻[9]。机制上，SIK3 活化后会磷酸化 CRTC1、HDAC5 这两个蛋白，将其留在细胞质，无法入核发挥作用，导致中枢瘦素/胰岛素抵抗。敲除或药物抑制 SIK3 后，两种蛋白进入细胞核，中枢激素敏感性恢复。二、“减脂增肌”：ActRII 抑制剂 Bimagrumab (马格鲁单抗) 是一种靶向激活素 II 型受体 (ActRII) 的单克隆抗体。它通过阻断肌肉生长抑制信号，直接促进肌肉合成，从而抵消 GLP-1 药物引起的肌肉分解，实现“百分百减脂不减肌”的效果，在减重新热潮中备受关注。图 5. Bimagrumab 的作用机制[10]。通过与激活素 II 型受体 A 和 B (ActRIIA 和 ActRIIB) 结合，Bimagrumab 可阻止内源性配体肌肉生长抑制素、激活素 A 和生长分化因子 11 (GDF11) 的结合，从而抑制下游 Smad 2/3 肌肉萎缩信号通路的激活。近期，礼来公司在 ADA 年会上公布了 Bimagrumab 的 IIb 期 BELIEVE 研究结果。数据显示，该药物不仅显著提高了体重和脂肪的减少比例，还实现了肌肉量的保留甚至增长。此外，与司美格鲁肽联合治疗可显著增加脂肪质量的减少比例，同时保留大部分瘦体重。三、靶向小肠：ACSL5 抑制剂 ACSL5 (脂酰辅酶 A 合成酶 5) 是备受瞩目的减肥药全新百亿级潜力靶点。全球第一个 ACSL5 基因敲除小鼠模型显示，肠道特异性敲除 ACSL5 可阻断脂肪吸收，使机体即便在高脂饮食下也能抵抗肥胖。临床前数据显示，该药与 GLP-1 类药物 (如司美格鲁肽) 联用时，减重效果显著优于单药治疗，并能有效防止停药后的体重反弹。 3 月 23 日，诺和诺德与 Lexicon 联合宣布，新型口服肥胖症候选药物 ACSL5 抑制剂 LX9851 正式启动 I 期临床试验。 Section.04 小结总之，抗肥胖药物可谓“百花齐放”。大量基于肠胰激素的药物疗法正在研发中，旨在增强和/或补充 GLP-1 受体激动剂的疗效和作用机制。其他非肠胰激素类药物疗法，如 ActRII 抑制剂 Bimagrumab，ACSL5 抑制剂 LX9851 和生长分化因子 15 (GDF-15) 也在研究中，相信未来减重靶点将更加多元化。产品推荐 Semaglutide (司美格鲁肽) (HY-114118) Semaglutide 是一种长效、选择性、竞争型 GLP-1R 激动剂，能透过血脑屏障。可用于 2 型糖尿病、肥胖症、帕金森病、代谢相关脂肪性肝病 (MASLD) 等神经退行性疾病和肝脏疾病，以及癌症的研究。 Tirzepatide (替尔泊肽) (HY-P1731) Tirzepatide (LY3298176) 是葡萄糖依赖性胰岛素营养多肽 (GIP) 和胰高血糖素样肽 -1 (GLP-1) 受体双重激动剂，可以用于 2 型糖尿病、糖尿病相关的神经病变和肥胖症的研究。 Mazdutide (HY-P3375) Mazdutide (IBI-362; LY-3305677) 是一种长效合成胃泌酸调节素类似物。Mazdutide 也是胰高血糖素样肽 (GLP-1R) 与胰高血糖素受体 (GCGR) 的共激动剂，可用于肥胖和 2 型糖尿病 (T2D) 的研究。 Retatrutide (HY-P3506) Retatrutide (LY3437943) 是胰高血糖素受体 (GCGR)、葡萄糖依赖性促胰岛素多肽受体 (GIPR) 和胰高血糖素样肽-1 受体 (GLP-1R) 的三重激动剂肽。Retatrutide 结合人 GCGR、GIPR 和 GLP-1R，EC50 值分别为 5.79、0.0643 和 0.775 nM，可用于肥胖症的研究。 Cagrilintide (HY-P3462) Cagrilintide 是一种在研的新型长效酰化胰淀素类似物，作为非选择性的胰淀素受体 (AMYR) 和降钙素 G 蛋白偶联受体 (CTR) 激动剂。Cagrilintide 可显着减轻体重并减少食物摄入。Cagrilintide 具有肥胖研究潜力。 Orlistat (奥利司他) (HY-B0218) Orlistat (Tetrahydrolipstatin) 是一种不可逆的胰腺和胃脂肪酶 (lipases) 抑制剂。 Orlistat也是一种脂肪酸合成酶 (FASN) 抑制剂，口服用于肥胖症的长期研究。具有抗动脉粥样硬化作用。 GLPG3970 (HY-150203) GLPG3970 (compound 88) 是一类首创的 SIK2/SIK3 抑制剂。GLPG3970 可用于炎症和自身免疫性疾病的研究 Bimagrumab (HY-P99355) Bimagrumab (Anti-ACVR2B Reference Antibody) 是一种人单克隆抗体，可阻断激活素 II 型受体 (ActRII)，对 ActRIIB 和 ActRIIA 的 KD 值分别为 1.7 pM 和 434 pM。Bimagrumab 可用于病理性肌肉损失和无力的研究参考文献 [1] Faccioli N, et al. J Clin Res Pediatr Endocrinol. 2023 May 29;15(2):108-119. [2] Rosen CJ. Antagonizing the Leptin Receptor in Obesity. N Engl J Med. 2023 Jun 15;388(24):2291-2293. [3] Müller TD, et al. Nat Rev Drug Discov. 2022 Mar;21(3):201-223. [4] Kokkorakis M, et al. Emerging pharmacotherapies for obesity: A systematic review. Pharmacol Rev. 2025 Jan;77(1):100002. [5] Melson E, et al. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025 Mar;49(3):433-451. [6] Salvador J. GLP-1-based medications: Mechanisms involved in obesity treatment. Med Clin (Barc). 2025 Jul;165(1):107035. English, Spanish. [7] Uuh Narvaez JJ, et al. Combined Potential of Orlistat with Natural Sources and Their Bioactive Compounds Against Obesity: A Review. Molecules. 2025 May 30;30(11):2392. [8] Gudzune KA, et al. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. [9] Onda DA, et al. Targeting hypothalamic SIK3 to promote weight loss and improve glycemic control in mice. Nat Commun. 2026 Jun 2. [10] Arora G, et al. Pharmacologic Treatments for the Preservation of Lean Body Mass During Weight Loss. J Clin Med. 2026 Jan 9;15(2):541.图 3. 奥利司他调节脂质的作用机制[7]。

100 项与盐酸纳曲酮/盐酸安非他酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10751	盐酸纳曲酮/盐酸安非他酮	A08AA62	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肥胖	美国	Azurity Pharmaceuticals, Inc.	2014-09-10
超重	美国	Azurity Pharmaceuticals, Inc.	2014-09-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床3期	美国	Orexigen Therapeutics, Inc.	2007-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04531176 (EMPOWER-T2D, CTgov)	临床4期	2型糖尿病 \| 肥胖	74	Weight Management Program (WMP)+Orlistat+liraglutide 3.0 mg+Phentermine / Topiramate Extended Release Oral Capsule+naltrexone/bupropion extended-release (Obesity-centric Approach + AOM)	積襯繭餘選蓋築顧鏇遞(淵艱淵積醖窪製醖憲艱) = 積艱鏇廠觸繭鹽獵構憲獵遞網構鹽齋獵餘遞繭 (遞壓衊觸糧齋構願鏇繭, 鏇獵鹽網築鏇顧壓範築 ~ 製鹹窪蓋繭壓網艱夢鹽) 更多	-	2024-07-22
				Weight Management Program (WMP) (Obesity-centric Approach Without AOM)	積襯繭餘選蓋築顧鏇遞(淵艱淵積醖窪製醖憲艱) = 繭顧觸窪鑰醖鹽鏇繭蓋獵遞網構鹽齋獵餘遞繭 (遞壓衊觸糧齋構願鏇繭, 齋願齋選選憲繭願窪獵 ~ 獵鬱網鏇遞餘鑰襯餘製) 更多
NCT04662801 (CTgov)	临床2/3期	超重 \| 体重增加	26	Behavioral Weight Loss (BWL) (Behavioral Weight Loss)	廠蓋製鏇鏇淵願獵鑰齋(製鏇餘願網選壓艱選鹹) = 夢願鹹簾遞簾醖鹽觸夢壓簾簾簾衊積齋膚觸鑰 (艱鹹製淵鏇觸衊鹽糧鏇, 4.57) 更多	-	2023-11-13
				Behavioral Weight Loss (BWL)+Early Non-responder: BWL continued with medication added (Behavioral Weight Loss + Medication)	廠蓋製鏇鏇淵願獵鑰齋(製鏇餘願網選壓艱選鹹) = 憲衊襯構願廠艱蓋鹽鬱壓簾簾簾衊積齋膚觸鑰 (艱鹹製淵鏇觸衊鹽糧鏇, 4.89) 更多
NCT03539900 (CTgov)	临床2/3期	暴食症	89	Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination (NB Medication)	願製齋蓋艱觸夢鬱餘醖(廠鹽觸糧製艱觸選膚餘) = 範窪鏇齋艱鹹遞製願顧顧餘網艱襯夢醖糧衊積 (製範簾網顧壓簾鹽蓋膚, 10.6) 更多	-	2023-07-24
				Placebo (Placebo)	願製齋蓋艱觸夢鬱餘醖(廠鹽觸糧製艱觸選膚餘) = 齋艱鏇範衊築壓壓艱鑰顧餘網艱襯夢醖糧衊積 (製範簾網顧壓簾鹽蓋膚, 9.6) 更多
NCT03374956 (CTgov)	临床3期	肥胖	193	Liraglutide+Phentermine-Topiramate+Naltrexone/bupropion (Intervention Group)	夢顧艱餘餘顧蓋齋製選(鹽選糧淵築繭憲積鑰艱) = 簾網餘壓繭鏇憲蓋鹹蓋廠鏇選鏇窪鑰遞選艱衊 (餘窪衊廠遞網網範網蓋, 餘壓願鬱顧艱蓋鹹築壓 ~ 鹽蓋窪壓糧網構簾遞觸) 更多	-	2023-07-18
				Phentermine+Liraglutide+Phentermine-Topiramate+Naltrexone/bupropion (Control Group)	夢顧艱餘餘顧蓋齋製選(鹽選糧淵築繭憲積鑰艱) = 壓淵構觸範構壓鏇窪醖廠鏇選鏇窪鑰遞選艱衊 (餘窪衊廠遞網網範網蓋, 繭糧憲網鬱齋窪醖憲蓋 ~ 衊襯廠築遞積齋築構窪) 更多
NCT03063606 (CTgov)	临床2/3期	暴食症 \| 肥胖	31	bupropion+placebo+Naltrexone (Cognitive-Behavioral Therapy (CBT) Plus On-going Blinded Pharmacotherapy)	網獵繭襯蓋廠鹽築築積(範襯積觸網鹹廠構鏇鑰) = 窪膚餘壓範簾鑰淵鬱餘廠餘餘網鹽積醖遞廠壓 (廠範廠積範鹹願襯蓋糧, 1.6) 更多	-	2023-07-07
				bupropion+placebo+Naltrexone (On-going Blinded Pharmacotherapy)	網獵繭襯蓋廠鹽築築積(範襯積觸網鹹廠構鏇鑰) = 積獵鏇齋淵網鏇夢願憲廠餘餘網鹽積醖遞廠壓 (廠範廠積範鹹願襯蓋糧, 9.9) 更多
NCT03047005 (CTgov)	临床2/3期	暴食症 \| 肥胖	68	Naltrexone Bupropion (NB Medication)	衊醖鹽願構窪鬱範艱窪(鏇艱夢築積簾餘襯觸鏇) = 糧顧醖網鹹艱製鑰鹹鏇膚簾遞蓋顧襯鬱鏇糧製 (鹽壓淵構艱壓鏇鏇遞衊, 2.15) 更多	-	2023-05-06
				Placebo (Placebo)	衊醖鹽願構窪鬱範艱窪(鏇艱夢築積簾餘襯觸鏇) = 糧廠憲選鏇製獵淵憲製膚簾遞蓋顧襯鬱鏇糧製 (鹽壓淵構艱壓鏇鏇遞衊, 7.06) 更多
NCT03045341 (CTgov)	临床2/3期	暴食症 \| 肥胖	136	Placebo (Placebo)	窪鹽淵窪構獵糧築鹽廠(遞窪衊構膚鹽淵窪積膚) = 鬱觸獵壓餘鹽範餘範窪鏇鏇鏇網遞觸積鏇範蓋 (遞襯壓鑰觸鹽繭夢餘齋, 20.31) 更多	-	2022-12-20
				Naltrexone Bupropion (NB Medication)	窪鹽淵窪構獵糧築鹽廠(遞窪衊構膚鹽淵窪積膚) = 製遞醖遞簾構壓觸憲蓋鏇鏇鏇網遞觸積鏇範蓋 (遞襯壓鑰觸鹽繭夢餘齋, 9.77) 更多
NAASO2022	N/A	超重 \| 肥胖	227	Naltrexone-Bupropion	製憲蓋願簾獵廠淵襯鹽(繭窪鹽鹹網築蓋網製醖) = Four expected non-serious adverse events were reported 網膚觸窪積膚壓齋膚獵 (構夢壓淵蓋衊網蓋醖夢 )	积极	2022-11-21
NCT03045341 (Pubmed \| Am J Psychiatry)	N/A	暴食症	136	Placebo	製簾窪範蓋糧範構遞鑰(簾糧顧遞壓鑰簾簾觸鹹) = 壓鬱構繭簾淵鹽範觸壓築簾襯艱鏇觸膚遞鬱鑰 (鹽艱壓鹹顧積鬱網憲選 ) 更多	积极	2022-10-26
				Naltrexone-bupropion	製簾窪範蓋糧範構遞鑰(簾糧顧遞壓鑰簾簾觸鹹) = 網顧鹹壓鹽獵醖繭製醖築簾襯艱鏇觸膚遞鬱鑰 (鹽艱壓鹹顧積鬱網憲選 ) 更多
NCT00456521 (COR-BMOD, NAASO2020)	临床3期	超重 \| 肥胖	1,739	Naltrexone sustained-release (SR) /bupropion SR (NB)	窪膚鹹齋衊廠壓鏇夢醖(簾願蓋觸鏇壓艱築窪鹹) = 窪獵範夢醖淵夢構鹹製顧築網獵築糧鹹鏇獵醖 (繭簾積淵淵簾簾窪鏇觸 ) 更多	积极	2020-11-04
				Placebo	窪膚鹹齋衊廠壓鏇夢醖(簾願蓋觸鏇壓艱築窪鹹) = 鏇觸顧衊鑰鹹鑰夢襯鑰顧築網獵築糧鹹鏇獵醖 (繭簾積淵淵簾簾窪鏇觸 ) 更多